A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). - Campone, Mario; Bachelot, Thomas; Treilleux, Isabelle; Pistilli, Barbara; Salleron, Julia; Seegers, Valérie; Arnedos, Monica; Loussouarn, Delphine; Wang, Qing; Vanlemmens, Laurence; Jimenez, Marta; Rios, Maria; et al. (European Journal of Cancer, 2021)